Somasundaram Venkatesan, Tevatia Manvir Singh, Purohit Abhishek, Ahuja Ankur, Mahapatra Manoranjan, Tyagi Seema, Pati Haraprasad, Saxena Renu
Department of Pathology, Armed Forces Medical College, Pune, 411040 India.
Brig Med, HQ Delhi Area, New Delhi, India.
Indian J Hematol Blood Transfus. 2017 Jun;33(2):169-174. doi: 10.1007/s12288-016-0707-6. Epub 2016 Jul 19.
Bone marrow microenvironment plays a crucial role in the growth of hemopoietic cells and bone marrow function, which in turn depends on an intact microvasculature. Our study assesses the microvessel density (MVD) in the bone marrow of aplastic anemia (AA) patients, compares with MVD of controls and MVD among the different types of AA. Bone marrow specimens from 60 patients with AA and 17 controls were studied. There were 33 patients with non severe AA (NSAA), 12 patients with severe AA (SAA) and 15 patients with very severe AA (VSAA). MVD was calculated on sections stained immunohistochemically for CD34. The mean bone marrow MVD in AA group was 1.28 ± 0.36, being significantly lower than that in control group (6.80 ± 1.59, < 0.001). MVD of SAA and NSAA patients were 1.16 ± 0.35 and 1.49 ± 0.27, respectively, being significantly different ( = 0.003). MVD of VSAA was 0.93 ± 0.25 and the difference with NSAA is significant, however there was no significant difference between SAA and VSAA. Bone marrow MVD is low in AA patients and is likely to have a role in pathophysiology of bone marrow failure. Proangiogenic agents together with specific therapy might accelerate the recovery of hematopoiesis in AA patients.
骨髓微环境在造血细胞生长和骨髓功能中起着关键作用,而骨髓功能又依赖于完整的微血管系统。我们的研究评估了再生障碍性贫血(AA)患者骨髓中的微血管密度(MVD),并与对照组的MVD以及不同类型AA之间的MVD进行比较。研究了60例AA患者和17例对照的骨髓标本。其中非重型AA(NSAA)患者33例,重型AA(SAA)患者12例,极重型AA(VSAA)患者15例。通过对免疫组化染色为CD34的切片计算MVD。AA组的平均骨髓MVD为1.28±0.36,显著低于对照组(6.80±1.59,<0.001)。SAA和NSAA患者的MVD分别为1.16±0.35和1.49±0.27,差异有统计学意义(=0.003)。VSAA的MVD为0.93±0.25,与NSAA的差异有统计学意义,但SAA和VSAA之间无显著差异。AA患者的骨髓MVD较低,可能在骨髓衰竭的病理生理学中起作用。促血管生成剂与特定治疗可能会加速AA患者造血功能的恢复。